Clinical Trials · NCT00288522

Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment

Name: Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 2Lanreotide

Phase: Phase 2
Recruitment status: Terminated
Sponsor: Ipsen
Enrollment: 5
Start date: Jan 2006
Locations: 1 site, Spain
Primary endpoint: Extraocular muscle infiltration and edema exam by evaluating (at Day 0 and Weeks 4, 8 and 12): extraocular muscle size, proptosis and intraocular pressure (tonometry)

View Lanreotide compound reference